On Oct. 19, the Food and Drug Administration (FDA) approved Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma. Read more
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.